‘Acute renal impairment’ warning added on Forxiga & Invokana

The Ministry of Food and Drug Safety(MFDS) gave an advance notice in regards to changes in the approval details of antidiabetic SGLT-2 inhibitors, ‘Forxiga(dapagliflozin)’ and ‘Invokana(canagliflozin)’ with the process of collecting opinions. The part to warn acute renal impairment was added.  

According to the MFDS on the 11^th, it judged necessity to change usage requirements for the U.S. FDA...